PBI-05204
Clinical foundation
Phoenix Biotechnology
A Conserved Stress Biology Platform.
For more than two decades, Phoenix Biotechnology has studied how defined botanical compounds interact with conserved cellular stress-response pathways and translated that work into drug candidates across antiviral, oncology, and neuroprotection applications. With human clinical experience and a global patent estate, the Phoenix Platform™ provides a foundation for therapeutic innovation across multiple disease areas.
Conserved stress biology
Phoenix Platform™
Antiviral
Oncology
Neuroprotection
// positioning
Many biotechnology companies are built around a single product or disease area.Phoenix Biotechnology is built around a scientific platform that can inform multiple therapeutic applications.
We believe understanding conserved cellular signaling pathways provides a durable foundation for discovery and translation.
// what we've built
The Phoenix Platform™
More than two decades of scientific development and over $30 million invested in research, intellectual property, software, formulation science, and translational development.
Explore the platform20+
Years of research
$30M+
Invested
20+
Granted patents
50+
Peer-reviewed publications
// foundation to forward
A foundation we keep building on.
PBI-05204 established a clinically characterized foundation through Phase I and Phase II studies, providing human safety and pharmacokinetic experience. PBI-06150 builds on that foundation as a defined, next-generation botanical drug candidate with a longer intellectual property runway and a development strategy informed by FDA's botanical drug framework.
PBI-06150
Lead forward asset
// principles
What guides our work.
Biology First
Platform Before Product
Scientific Credibility
Biological Intelligence
Translation
Long-Term Platform Value
// next
Building from biology, not just products.
Learn how the Phoenix Platform™ applies insights from conserved stress biology across discovery and translational development.